# SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

Study · id `cardio:ct-nct06955260` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06955260](<https://clinicaltrials.gov/study/NCT06955260>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06955260

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 410 participants.

## Technical summary

Registry record NCT06955260. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 410 participants (planned count; ClinicalTrials.gov record NCT06955260, source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)
- Started: 2026-05-29 (actual) (ClinicalTrials.gov record NCT06955260, source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06955260, source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)
- Completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT06955260, source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06955260, source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06955260-2026-09-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
- Acronym: EMPA-HEART-3
- Condition: Congenital Heart Disease
- Intervention (Drug): Empagliflozin 10 mg
- Intervention (Other): Placebo
- Lead sponsor: Subodh Verma
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY
- Collaborator: Applied Health Research Centre
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Adult congenital heart disease (`cardio:adult-congenital-heart-disease`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Applied Health Research Centre (`cardio:org-applied-health-research-centre`)

## Provenance

Content hash: 25bbaaefcd9a22dc21a5f1c014b6aa86e33b67c7db089750a0171420054a9a54
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
